Shang Hai Zheng Quan Bao·2025-10-31 18:19Core Viewpoint - The company is changing the use of part of its raised funds from the "Hemoporfin US Registration Project" to the "Photodynamic Drug Innovation R&D Sustainable Development Project" to enhance fund utilization efficiency and focus on advantageous R&D areas [1][8][20]. Summary by Sections 1. Overview of Fundraising Project Change - The original project name was "Hemoporfin US Registration Project," which is now changed to "Photodynamic Drug Innovation R&D Sustainable Development Project" [1]. - The amount of funds redirected is RMB 181.5461 million, which includes interest and investment income as of October 30, 2025 [1][7]. - The new project construction period is from the date of shareholder meeting approval until December 31, 2027 [1][9]. 2. Fundraising Basic Information - The company raised a total of RMB 1.074 billion by issuing 120 million shares at RMB 8.95 per share, with a net amount of RMB 974.3239 million after deducting issuance costs [2]. - The funds have been stored in a dedicated account, ensuring effective supervision [2]. 3. Reasons for Change - The change is due to slower-than-expected clinical research progress influenced by international environments and regulatory policies [8][20]. - The original project will continue as a sub-project under the new project, focusing on the ongoing Phase II clinical research in the US [9][20]. 4. New Project Details - The new project includes various initiatives such as expanding indications for the drug Ameluz, which is used for treating precancerous lesions and other conditions [12][14]. - The company plans to continue developing its photodynamic technology platform, which has shown significant clinical advantages [17][18]. 5. Market Outlook - The company is a leader in the photodynamic drug market, with a strong pipeline and a focus on expanding its product offerings [17][19]. - The photodynamic therapy market is growing due to its unique therapeutic value in treating various conditions [17][18]. 6. Approval Process - The board of directors and the supervisory board have approved the change, which will be submitted for shareholder approval [23][24].